Evaluation of Modified 2-Tiered Serodiagnostic Testing Algorithms for Early Lyme Disease

Background The conventional 2-tiered serologic testing protocol for Lyme disease (LD), an enzyme immunoassay (EIA) followed by immunoglobulin M and immunoglobulin G Western blots, performs well in late-stage LD but is insensitive in patients with erythema migrans (EM), the most common manifestation of the illness. Western blots are also complex, difficult to interpret, and relatively expensive. In an effort to improve test performance and simplify testing in early LD, we evaluated several modified 2-tiered testing (MTTT) protocols, which use 2 assays designed as first-tier tests sequentially, without the need of Western blots. Methods The MTTT protocols included (1) a whole-cell sonicate (WCS) EIA followed by a C6 EIA; (2) a WCS EIA followed by a VlsE chemiluminescence immunoassay (CLIA); and (3) a variable major protein-like sequence, expressed (VlsE) CLIA followed by a C6 EIA. Sensitivity was determined using serum from 55 patients with erythema migrans; specificity was determined using serum from 50 patients with other illnesses and 1227 healthy subjects. Results Sensitivity of the various MTTT protocols in patients with acute erythema migrans ranged from 36% (95% confidence interval [CI], 25%-50%) to 54% (95% CI, 42%-67%), compared with 25% (95% CI, 16%-38%) using the conventional protocol (P = .003-0.3). Among control subjects, the 3 MTTT protocols were similarly specific (99.3%-99.5%) compared with conventional 2-tiered testing (99.5% specificity; P = .6-1.0). Conclusions Although there were minor differences in sensitivity and specificity among MTTT protocols, each provides comparable or greater sensitivity in acute EM, and similar specificity compared with conventional 2-tiered testing, obviating the need for Western blots.

[1]  A. Steere,et al.  The presenting manifestations of Lyme disease and the outcomes of treatment. , 2003, The New England journal of medicine.

[2]  M. Schriefer,et al.  Evaluation of the Recombinant VlsE-Based Liaison Chemiluminescence Immunoassay for Detection of Borrelia burgdorferi and Diagnosis of Lyme Disease , 2008, Clinical and Vaccine Immunology.

[3]  G. Wormser,et al.  Comparative Cost-Effectiveness of Two-Tiered Testing Strategies for Serodiagnosis of Lyme Disease with Noncutaneous Manifestations , 2013, Journal of Clinical Microbiology.

[4]  Barbara J. B. Johnson,et al.  Dominant Epitopes of the C6 Diagnostic Peptide of Borrelia burgdorferi Are Largely Inaccessible to Antibody on the Parent VlsE Molecule , 2007, Clinical and Vaccine Immunology.

[5]  A. Steere,et al.  Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Delorey,et al.  Lyme Borreliosis Serology: Performance of Several Commonly Used Laboratory Diagnostic Tests and a Large Resource Panel of Well-Characterized Patient Samples , 2016, Journal of Clinical Microbiology.

[7]  R Ruthazer,et al.  Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Susan C. Lipsett,et al.  False Positive Lyme Disease IgM Immunoblots in Children. , 2016, The Journal of pediatrics.

[9]  A. Steere,et al.  Performance of United States serologic assays in the diagnosis of Lyme borreliosis acquired in Europe. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Nowakowski,et al.  Serodiagnosis in early Lyme disease , 1993, Journal of clinical microbiology.

[11]  R. Nadelman,et al.  Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  A. Hinckley,et al.  Lyme disease testing by large commercial laboratories in the United States. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  G. Wormser,et al.  High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  A. Steere,et al.  Cellular and Humoral Immune Responses toBorrelia burgdorferi Antigens in Patients with Culture-Positive Early Lyme Disease , 2001, Infection and Immunity.

[15]  R. Nadelman,et al.  Comparison of five diagnostic modalities for direct detection of Borrelia burgdorferi in patients with early Lyme disease. , 2012, Diagnostic microbiology and infectious disease.

[16]  P. Mead,et al.  Current Guidelines, Common Clinical Pitfalls, and Future Directions for Laboratory Diagnosis of Lyme Disease, United States , 2016, Emerging infectious diseases.

[17]  Helmut Kerl,et al.  Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients. , 2006, Archives of dermatology.

[18]  Susan C. Lipsett,et al.  Evaluation of the C6 Lyme Enzyme Immunoassay for the Diagnosis of Lyme Disease in Children and Adolescents. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  C. Beard,et al.  Collection and Characterization of Samples for Establishment of a Serum Repository for Lyme Disease Diagnostic Test Development and Evaluation , 2014, Journal of Clinical Microbiology.

[20]  A. Steere,et al.  Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis. , 2011, Arthritis and rheumatism.

[21]  A. Steere,et al.  Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. , 2013, Diagnostic microbiology and infectious disease.

[22]  A. Steere,et al.  2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Crystal Structure of Lyme Disease Variable Surface Antigen VlsE of Borrelia burgdorferi * , 2002, The Journal of Biological Chemistry.

[24]  M. LantosPaul,et al.  Empiric Antibiotic Treatment of Erythema Migrans-Like Skin Lesions As a Function of Geography: A Clinical and Cost Effectiveness Modeling Study , 2013 .

[25]  Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. , 1995, MMWR. Morbidity and mortality weekly report.

[26]  A. Steere,et al.  Serodiagnosis of Lyme Disease by Kinetic Enzyme-Linked Immunosorbent Assay Using Recombinant VlsE1 or Peptide Antigens of Borrelia burgdorferi Compared with 2-Tiered Testing Using Whole-Cell Lysates , 2003, The Journal of infectious diseases.

[27]  M. Gerber,et al.  Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  A. Steere,et al.  Prospective study of serologic tests for lyme disease. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  R. Nadelman,et al.  Impact of Clinical Variables on Borrelia burgdorferi-Specific Antibody Seropositivity in Acute-Phase Sera from Patients in North America with Culture-Confirmed Early Lyme Disease , 2008, Clinical and Vaccine Immunology.